Synsorb Biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synsorb Biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: Fred J Bealle who wrote ()	6/5/1997 2:09:00 AM
From: The Count	of 32

NEWS RELEASE: Synsorb Biotech Inc - News Release Second US patent for Synsorb Cd Synsorb Biotech Inc SYB Shares issued 16084520 1997-06-03 close $9 Wednesday Jun 4 1997 News Release Mr David Rafter reports The US Patent and Trademark Office has issued patent 5,635,606 to the company effective June 3 1997. The patent, issued in the US, relates to the pharmaceutical use of Synsorb Cd for the treatment of recurring antibiotic associated diarrhea. The compounds named in the patent relate to specific Synsorbs which bind the toxin secreted by C. difficile bacteria thereby preventing them from colonizing the intestinal tract and inducing the symptoms of the disease. This patent substantially broadens the company's proprietary position with respect to the treatment of Clostridium difficile associated diarrhea. C. difficile associated diarrhea (CDAD) is one of the most common hospital borne infections and is a growing threat to hospitalized patients in North America and Europe. Up to 8.75 million North Americans, Western Europeans and Japanese contract the infection each year, usually as a result of antibiotic therapy administered to treat other conditions. Of these, up to 20% suffer a recurring form of the disease which can lead to serious complications, including pseudomembranous colitis, ulceration of the colon and sometimes death. Synsorb Biotech is currently conducting an 18 centre cross-Canada phase II clinical trial to investigate the product's effectiveness in treating recurring C. difficile infections. Synsorb Cd is the company's second product under clinical investigation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext